【G.N.Airloop】June 2026 Financial Results | Details of Fundraising and Financial Covenants

Fundraising and Contract Details

G.N.Airloop entered into a loan agreement for 20,000 million yen on June 26, 2026, scheduled to be executed on July 1, 2026. The lenders are Mizuho Bank and SBI Shinsei Bank, with collateral provided in the form of ordinary shares of its subsidiary Gyre Therapeutics, Inc. The agreement includes financial covenants requiring the company to maintain total capital of at least 75% from the fiscal year ending December 2026 onward and to ensure that consolidated operating profit or net income does not turn negative. The funds are intended for expenses related to acquiring shares of Aum Pharmaceutical Holdings. The impact on future performance is under review.

Outlook and Impact

The funds raised are intended to finance the acquisition of shares of Aum Pharmaceutical Holdings, with financial covenants requiring the company to maintain financial soundness and profitability. Completion of the fundraising and adherence to contract conditions are expected to significantly influence future business operations and financial stability. G.N.Airloop will continue to focus on capital policy and financial management to ensure stable performance and growth.